Sam Chun Dang Pharm

Bio & Pharma Chong Kun Dang to build new plant for foray into biologics market

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Aerospace & Defense S.Korea’s Hanwha eyes L-SAM exports with UAE’s EDGE  

Hanwha Group’s Vice Chairman and heir apparent Kim Dong-kwan is on the front line to export South Korea's latest homegrown air defense system ...

Artificial intelligence OpenAI, SoftBank tap Samsung for Stargate AI initiative

Samsung Electronics Co. Chairman Lee Jae-yong discussed potential collaboration on the Stargate AI initiative with OpenAI co-founder and CEO Sam Alt...

Corporate governance Hanmi Pharm’s chair poised to win management feud with her son

Hanmi Pharmaceutical Group Chairman Song Young-sook is poised to claim victory in a year-long dispute with her eldest son Lim Jong-yoon to take cont...

Private equity La Defense might have a say over Hanmi Pharm's family feud

La Defense Partners is expected to exercise a casting vote over the ongoing management dispute at Hanmi Science Co. after the Seoul-based private eq...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Korean stock market MSCI Korea Index adds Hyundai Rotem

MSCI announced on Wednesday that South Korea's Hyundai Rotem Co. will be added to the Morgan Stanley Capital International (MSCI) Korea Index. ...

Aerospace & Defense S.Korea’s LIG Nex1, Iraq set for $2.6 billion deal on M-SAM missile system

Iraq has decided to import South Korean-made mid-range surface-to-air missile (M-SAM) system II, known as Cheongung II, in a deal estimated at $2.6 ...

Pension funds NPS signals more say in Hanmi Pharmaceutical's family feud

South Korea’s National Pension Service is indicating more active involvement in the management of Hanmi Pharmaceutical Group embroiled in a ye...

Bio & Pharma Celltrion scraps merger with Celltrion Pharm

South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&...

Bio & Pharma GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn

South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...

Aerospace & Defense LIG Nex1 participates in Malaysia's DSA 2024

South Korea's major defense system developer LIG Nex1 Co. announced on Tuesday that it's participating in the Defence Services Asia (DSA) 2024 exhib...

Bio & Pharma Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozi...

Bio & Pharma Chong Kun Dang rallies on $1.3 bn deal with Novartis

Chong Kun Dang Pharmaceutical Corp.'s shares zoomed more than 25% on Monday on news that the South Korean medicine developer has signed its biggest-...

Bio & Pharma Celltrion Pharm gets GMP certification from Japan

Celltrion Pharm Inc. announced on Wednesday that its pre-filled syringe (PFS) production facility in Cheongju, North Chungcheong Province has obtain...

Bio & Pharma Yungjin Pharm's new drug candidate gets Fast Track from FDA

South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...

Bio & Pharma Hanmi Pharm to start global clinical trials for immune-oncology drug

South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...

Bio & Pharma Dongwha Pharm to buy Vietnamese pharmacy chain at $30 mn

South Korea's Dongwha Pharm announced on Thursday that it signed an agreement to acquire a 51% stake in Trung Son Pharma, a leading pharmacy chain i...

Bio & Pharma Hanmi Pharm to develop obesity drug customized for S.Korean

South Korea's Hanmi Pharmaceutical Co. plans to develop the GLP-1 class "Epeglenatide," which it received as a technology return from Sanofi S.A., i...

Tech, Media & Telecom Tinder owner Match Group taps Sam Ahn as Asia's chief innovation officer

Match Group Inc., operating online dating and chat platforms like Tinder, Hinge and OkCupid in some 40 languages, has appointed its subsidiary Hyper...

Bio & Pharma Daehwa Pharm applies for approval of anti-dementia patch in China

South Korea's Daehwa Pharm Co. is speeding up its advance into the Chinese market for anti-dementia medicine, applying for sales approval of its pat...

Bio & Pharma Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean ph...

Artificial intelligence OpenAI’s Sam Altman seeks help from Korean startups, chipmakers

Sam Altman, chief executive of Microsoft-backed OpenAI and ChatGPT creator, said on Friday that he hopes to collaborate with South Korean developers...

Private equity Affinity Equity Partners’ Korea head Sam Lee resigns

Affinity Equity Partners’ Seoul office head Sam Lee has left the global investment firm, sources familiar with the matter told The Korea Econo...

Bio & Pharma S.Korea's ST Pharm supplies $49 mn worth of APIs to European drug firm

ST Pharm Co., a South Korean pharmaceutical firm, announced on Thursday that it had entered into an agreement to supply oligonucleotides to an undis...

Bio & Pharma Korea's ST Pharm completes new R&D hub for gene therapy

ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&...

Bio & Pharma Korea United Pharm signs contract to supply medicines to Saudi Arabia

Korea United Pharm. Inc. announced on Monday that it signed a contract to supply nine types of medicines, including 11 anticancer drugs, to Saudi ph...

Bio & Pharma Brazil approves Celltrion Pharm’s syringe facility

Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...

Bio & Pharma Chong Kun Dang, Synaffix ink deal to introduce ADC technology

Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a contract with Dutch biotechnology firm Synaffix B.V for the use of antibody-...

Bio & Pharma Ybrain, Chong Kun Dang join forces for digital medicine distribution

South Korean electroceutical platform company Ybrain Inc. said on Tuesday it has entered into a joint promotion agreement with Chong Kun Dang Pharma...